319 related articles for article (PubMed ID: 24650154)
1. Safinamide for the treatment of Parkinson's disease.
Dézsi L; Vécsei L
Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
[TBL] [Abstract][Full Text] [Related]
2. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
5. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
Müller T; Foley P
Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
[TBL] [Abstract][Full Text] [Related]
7. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller T
Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
[TBL] [Abstract][Full Text] [Related]
8. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Chazot PL
Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi F; Torti M
Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
[TBL] [Abstract][Full Text] [Related]
10. Safinamide for symptoms of Parkinson's disease.
Müller T
Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
[TBL] [Abstract][Full Text] [Related]
11. An expert opinion on safinamide in Parkinson's disease.
Onofrj M; Bonanni L; Thomas A
Expert Opin Investig Drugs; 2008 Jul; 17(7):1115-25. PubMed ID: 18549347
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
[TBL] [Abstract][Full Text] [Related]
13. Monoamine Oxidase B Inhibitors in Parkinson's Disease.
Dezsi L; Vecsei L
CNS Neurol Disord Drug Targets; 2017; 16(4):425-439. PubMed ID: 28124620
[TBL] [Abstract][Full Text] [Related]
14. Safinamide for the treatment of Parkinson's disease.
deSouza RM; Schapira A
Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
Stocchi F; Borgohain R; Onofrj M; Schapira AH; Bhatt M; Lucini V; Giuliani R; Anand R;
Mov Disord; 2012 Jan; 27(1):106-12. PubMed ID: 21913224
[TBL] [Abstract][Full Text] [Related]
17. ▼ Safinamide for Parkinson's disease.
Drug Ther Bull; 2018 May; 56(5):54-57. PubMed ID: 29760163
[TBL] [Abstract][Full Text] [Related]
18. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
Cattaneo C; Sardina M; Bonizzoni E
J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
[TBL] [Abstract][Full Text] [Related]
19. Real life evaluation of safinamide effectiveness in Parkinson's disease.
Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
[TBL] [Abstract][Full Text] [Related]
20. Safinamide: first global approval.
Deeks ED
Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
